Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
87.32
+2.57 (3.03%)
At close: Jun 26, 2026, 4:00 PM EDT
87.28
-0.04 (-0.05%)
After-hours: Jun 26, 2026, 7:54 PM EDT
Corcept Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Corcept Therapeutics stock have an average target of 97.5, with a low estimate of 72 and a high estimate of 135. The average target predicts an increase of 11.66% from the current stock price of 87.32.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Corcept Therapeutics stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $88 | Buy | Reiterates | $88 | +0.78% | Jun 1, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $95 | Buy | Maintains | $95 | +8.80% | Jun 1, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $110 → $135 | Buy | Reiterates | $110 → $135 | +54.60% | May 28, 2026 |
| UBS | UBS | Buy Upgrades $72 | Buy | Upgrades | $72 | -17.54% | May 13, 2026 |
| Wolfe Research | Wolfe Research | Hold Upgrades n/a | Hold | Upgrades | n/a | n/a | Mar 26, 2026 |
Financial Forecast
Revenue This Year
988.62M
from 761.41M
Increased by 29.84%
Revenue Next Year
1.40B
from 988.62M
Increased by 41.62%
EPS This Year
0.49
from 0.82
Decreased by -40.55%
EPS Next Year
2.50
from 0.49
Increased by 411.79%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.0B | 1.9B | |
| Avg | 988.6M | 1.4B | |
| Low | 918.8M | 1.0B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 34.7% | 93.3% | |
| Avg | 29.8% | 41.6% | |
| Low | 20.7% | 1.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | 0.49 | 2.50 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -40.5% | 411.8% | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.